This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.
Top Analyst Reports for Microsoft, Nike & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Nike (NKE), and Novo Nordisk (NVO).
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
by Kinjel Shah
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity
by Zacks Equity Research
Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.
Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment
by Zacks Equity Research
Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.
Intercept (ICPT) Ocaliva's Prescribing Information Updated
by Zacks Equity Research
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Deere, BHP Group and Manulife Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Deere, BHP Group and Manulife Financial
Lilly's (LLY) Fifth Tirzepatide Study Meets All Key Endpoints
by Zacks Equity Research
Lilly's (LLY) SURPASS-4 study evaluating tirzepatide against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk meets all primary and key secondary endpoints.
Top Research Reports for Novo Nordisk, IBM, & Deere
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk AS (NVO), International Business Machines Corporation (IBM), and Deere & Company (DE).
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.
PFE vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.
Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.
Novo Nordisk (NVO) to Begin Study on Oral Semaglutide in Obesity
by Zacks Equity Research
Novo Nordisk (NVO) to start a phase IIIa study testing oral semaglutide 50 mg in people with obesity or those who are overweight with comorbidities. The study is expected to begin in second-half 2021.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Honeywell International, Novo Nordisk and Starbucks
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Honeywell International, Novo Nordisk and Starbucks
Top Stock Reports for Microsoft, JPMorgan & Honeywell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), JPMorgan (JPM), and Honeywell (HON).
AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal
by Zacks Equity Research
AstraZeneca's (AZN) phase III study on Farxiga in hospitalized COVID-19 patients with pre-existing health conditions fails to show statistical significance for the primary endpoint
Top Analyst Reports for Facebook, Adobe & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe (ADBE), and Novo Nordisk (NVO).
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
by Zacks Equity Research
Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
The Zacks Analyst Blog Highlights: Novo Nordisk, NextEra Energy, 3M Co, General Motors and U.S. Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, NextEra Energy, 3M Co, General Motors and U.S. Bancorp
Top Analyst Reports for Novo Nordisk, NextEra & 3M Company
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), NextEra Energy (NEE), and 3M Company (MMM).
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.
Top Research Reports for Berkshire Hathaway, Walmart & Home Depot
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Walmart (WMT) and Home Depot (HD).